Announced during last month’s 7th edition of BioFIT – Fostering Innovation & Transfer conference, 04 – 05 December, Marseille, France, we are delighted to announce that VHIO-born spin-off, Peptomyc S.L., co-founded in 2014 by VHIO’s Laura Soucek, also CEO of the enterprise, PI of our Mouse Models of Cancer Therapies Group and ICREA Professor, has picked up its final prize for this year.
Co-led by Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of Peptomyc and formerly a Postdoctoral Fellow in Laura’s lab at VHIO, the company’s research team (see http://www.peptomyc.com/team), centers on developing anti-Myc peptides for the treatment of non-small cell lung cancer, triple negative breast cancer and glioblastoma. The Omomyc cell-penetrating peptide (CPP), proven preclinically thanks to research pioneered by Laura over the last 20 years, promises to become the first ever clinically viable and direct inhibitor of Myc – a protein implicated in the formation of most tumor types.
On the occasion of this year’s BioFIT meeting – Europe’s premier event for early-stage innovations in Life Sciences, among the total of 80 applications, 20 projects were shortlisted by a jury of international experts and selected to present during the Start-up Slams competition.
At the end of the two-day conference, Peptomyc was jointly awarded as the Most Innovative Life Sciences Start-up of 2018, alongside the company Elasmogen that develops next generation therapeutic biologics for the treatment of inflammatory diseases.
To discover more about this important recognition as well as BioFIT, please access the corresponding press release by clicking on the following link: https://www.biofit-event.com/wp-content/uploads/2018/12/CP-Bilan-BioFIT-2018-VF-UK-1.pdf .